GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Short Percentage of Float

Celyad Oncology (XBRU:CYAD) Short Percentage of Float


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Celyad Oncology's Short Percentage of Float

For the Biotechnology subindustry, Celyad Oncology's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Short Percentage of Float falls into.


Celyad Oncology (XBRU:CYAD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Short Percentage of Float
Comparable Companies
XBRU:ALIMG XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB
Traded in Other Exchanges
1C0:Germany
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Website
https://www.celyad.com
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines